70 results
Embolic protection, TAVI, heart failure and artificial intelligence: what's new in 2023
19 May 2023 – From EuroPCR 2023
This session covers various topics related to transcatheter aortic valve replacement, including the Protect Head-to-Head study on full-body embolic protection during TAVR, the FLOWer device for complete embolic protection, the use of a pulsing aspiration pump for percutaneous thrombectomy, and many more innovation updates from 2023.
How have REVIVED (percutaneous revascularization for ischemic left ventricular dysfunction) results changed my practice?
17 May 2023 – From EuroPCR 2023
Mirvat Alasnag and Ajay Kirtane reflect on the REVIVED (percutaneous revascularization for ischemic left ventricular dysfunction) randomised trial 9 months after its release. They discuss how the unexpected results had an effect on their practice, and how results compare to those of the STICH trial.
Outcomes of medical therapy plus PCI for multivessel or left main CAD ineligible for surgery
09 Mar 2023
The OPTIMUM study evaluates the outcomes in patients with complex CAD, including significant LM disease, its equivalent, or MVD CAD, undergoing percutaneous revascularization in addition to guideline directed medical therapy (GDMT) versus GDMT alone.
Reviewer
Reviewer
AIMI-HF trial - Ischemia and viability imaging in heart failure: The alternative imaging modalities in ischemic heart failure trial
05 Mar 2023
Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.
Author
Effect of myocardial viability, percutaneous coronary intervention and functional recovery on clinical outcomes in the REVIVED-BCIS2 randomized trial
13 Mar 2023
Dejan Milasinovic provides his take on this clinical trial which was presented by Divaka Perera (London, United Kingdom), at the American College of Cardiology (ACC/WCC) 2023 Scientific Session.
Author
Clinical and economic burden of reduced PCI access during UK COVID-19 lockdown – A We CARE analysis
18 May 2022 – From EuroPCR 2022
Across Europe, during the COVID pandemic, there was a big reduction in patients presenting for primary PCI. Interviewed by Nicola Ryan, Mamas Mamas summarises the key points from the We CARE study which analysed the effect at the population level in terms of heart failure diagnosis, cost...
Interventions for hypertension and heart failure
19 May 2022 – From EuroPCR 2022
View slides and videos on procedures for hypertension and heart failure including observations and outcomes from the RELIEVE-HF roll-in cohort, a novel approach for performing renal denervation, RDN registry of a resistant hypertension multidisciplinary team..
PCR Innovators Day - Follow-up and technology updates
19 May 2022 – From EuroPCR 2022
In this EuroPCR 2022 session, find out more about how mastering heart failure treatment by empowering physicians and patients, discover a novel approach for fluid removal, an adjustable interatrial shunt system, and much more!
Treating ASD and VSD in heart failure patients
17 May 2022 – From EuroPCR 2022
Consult this session to learn more about the treatment of atrial septal defect and ventricular septal defect in heart failure patients with a selection of complex cases: atrial septal defect in a patient with dextrocardia, NobleStitch failure after a percutaneous PFO closure, ventricular septal defect after...
Moderate aortic stenosis in patients with heart failure and reduced ejection fraction
08 Jun 2021
The aim of this study was to determine the prognostic impact conferred by the presence of moderate AS on the outcomes of patients with HFrEF.
Reviewer
